BLVIS A Blue Vision A

Managers’ transactions

Managers’ transactions

May 25,2023 

Announcement no. 32 

  

Managers’ transactions  

Pharma Equity Group A/S has today received notification pursuant to article 19 of Regulation (EU) no. 596/2014 of the below transactions related to shares in Pharma Equity Group A/S made by persons discharging managerial responsibilities in Pharma Equity Group and/or persons closely related with them.   

  

 

  

1. Details of the person discharging managerial responsibilities/person closely associated  


a) Name   		  

Thomas Kaas Selsø 


2. Reason for the notification  


 a) Position/status   		 

CEO 
  

b) Initial notification/amendment   		  

Initial notification  
 

3. Details of the issuer  
  

a) Name   		 

Pharma Equity Group A/S  
   

b) LEI   		 

 2138008SUI4D917FKN20   
 

c) Trade name  		  

PEG 
  

4. Details of the transaction(s)  
  

a) Description of the financial instrument, type    of instrument and Identification code   		 

Shares, ISIN code DK0061155009 
  

b) Nature of the transaction   		 

Purchase  
  

c) Price(s) and volume(s)  

Price: DKK 167,225



Volume: 551,724  
   

d) Aggregated information  

- Aggregated volume  

- Aggregated price   		 

N/A  
  

e) Date of the transaction   		  

25-05-2023, 09:26 CEST 
 

 f) Place of the transaction   		 

Nasdaq Copenhagen A/S 





For further information, please contact:  

  

Thomas Kaas Selsø, CEO of Pharma Equity Group A/S, phone: 40 22 21 14 

Peter M. Eriksen, Chair of the Board of Directors of Pharma Equity Group A/S, phone: 51 99 66 00. 



EN
25/05/2023

Underlying

BLVIS ABlue Vision A

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Blue Vision A

 PRESS RELEASE
Free
BLVIS A BLUE VISION A

Indkaldelse til ordinær generalforsamling i Pharma Equity Group A/S

Indkaldelse til ordinær generalforsamling i Pharma Equity Group A/S 25. marts 2026 Meddelelse nr. 4 Indkaldelse til ordinær generalforsamling i Pharma Equity Group A/S Bestyrelsen indkalder hermed til den ordinære generalforsamling i Pharma Equity Group A/S (“PEG” eller “Selskabet”) den: 16. april 2026, kl. 15:30 på adressen Wihlborgs KantinerSlotsmarken 152970 Hørsholm Dagsordenen for den ordinære generalforsamling er følgende: Bestyrelsens beretning om Selskabets virksomhed det forløbne årFremlæggelse af revideret årsrapport til godkendelseMeddelelse af decharge for bestyrelsen og...

March 25, 2026 1 EN
 PRESS RELEASE
Free
BLVIS A BLUE VISION A

Notice convening the annual general meeting in Pharma Equity Group A/S

Notice convening the annual general meeting in Pharma Equity Group A/S 25 March 2026 Announcement no. 4 Notice convening the annual general meeting in Pharma Equity Group A/S The board of directors hereby convenes the annual general meeting in Pharma Equity Group A/S (“PEG” or the “Company”) to be held on: 16 April 2026, at 3.30 PM CEST at Wihlborgs CanteensSlotsmarken 15DK-2970 Hørsholm The agenda for the annual general meeting is as follows: The board of directors' report on the Company's activities in the past yearPresentation of the audited annual report for approvalDischarge to...

March 25, 2026 1 EN
 PRESS RELEASE
Free
BLVIS A BLUE VISION A

Pharma Equity Group A/S - Årsrapport 2025

Pharma Equity Group A/S - Årsrapport 2025 25 March 2026 Announcement no. 3 Pharma Equity Group A/S - Årsrapport 2025 Pharma Equity Group A/S - Årsrapport 2025 - året i hovedtræk Bestyrelsen for Pharma Equity Group A/S har dags dato behandlet og godkendt Selskabets årsrapport for 2025, som i hovedtræk kan sammenfattes som følger: Reponex Pharmaceuticals A/S har i 2025 opnået myndighedsgodkendelse til at igangsætte et pivotalt fase 2-studie med RNX-011 til behandling af sekundær bakteriel bughindebetændelse.RNX-051 er i 2025 blevet videreudviklet gennem fortsat udviklingsarbejde, yderlig...

March 25, 2026 1 EN
 PRESS RELEASE
Free
BLVIS A BLUE VISION A

Pharma Equity Group A/S - Annual Report 2025

Pharma Equity Group A/S - Annual Report 2025 25 March 2026 Announcement no. 3 Pharma Equity Group A/S - Annual Report 2025 Pharma Equity Group A/S - Annual Report 2025 – Highlights of the year Today, the Board of Directors of Pharma Equity Group A/S reviewed and approved the Company’s Annual Report for 2025, the key highlights of which are as follows: In 2025, Reponex Pharmaceuticals A/S obtained regulatory approval to initiate a pivotal Phase 2 trial of RNX-011 for the treatment of secondary bacterial peritonitis.In 2025, RNX-051 was further advanced through continued development work...

March 25, 2026 1 EN
 PRESS RELEASE
Free
BLVIS A BLUE VISION A

OPDATERING AF FINANSKALENDER FOR 2026

OPDATERING AF FINANSKALENDER FOR 2026 OPDATERING AF FINANSKALENDER FOR 2026 Hørsholm 18. marts 2026 Selskabsmeddelelse nr. 2 Pharma Equity Group A/S foretager en rettelse til finanskalenderen for 2026. Offentliggørelsen af årsregnskabet flyttes af tekniske årsager fra 18. marts 2026 til 25. marts 2026. Datoen for afholdelse af ordinær generalforsamling fastholdes til 16. april 2026.  Pharma Equity GroupFinanskalender for 2026 4. martsFrist for aktionærforslag - Ordinær generalforsamling 25. marts Årsrapport 2025 16. aprilOrdinær generalforsamling 14. augustDelårsrapport – for halvåret, d...

March 18, 2026 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch